Kyprolis sales for the second quarter were reported---211 million, up 23% year on year.
From the Amgen conference call, "KYPROLIS grew 23% year-over-year, led by our successful launch efforts across existing and new markets outside the United States. Uptake continues to be robust across the launch markets with a 20% sequential volume growth. As Bob mentioned, KYPROLIS has developed two sets of exciting overall survival data in relapsed multiple myeloma patients this year. Earlier in the year in the head-to-head ENDEAVOR study against VELCADE, we demonstrated that the KRYPOLIS arm reduced the risk of death by 21% and improved overall survival by about eight months compared to the VELCADE arm. Just recently, the ASPIRE study demonstrated that adding KYPROLIS to REVLIMID and dexamethasone also reduced the risk of death by 21% and improves survival by about eight months. It is clear. Multiple myeloma patients live longer when treated with KYPROLIS."
Amgen's success with Kyprolis, will provide incentives to add Captisol to other products. This success will encourage wider usage by other companies. Seems to be a source a added growth for Ligand.
Amgen reports quarter results on Tuesday. Are there any expectations for Kyprolis?
LGND partner Aldeyra completes patient dosing in DED P2 trial:
Quarterly results from Novartis: Promacta sales in the quarter were 210 million dollars, "Promacta/Revolade (USD 210 million, +35% cc) grew at a strong double-digit rate, driven by continued worldwide uptake as well as growth of the thrombopoietin class for chronic immune thrombocytopenic purpura."
Will the 10m buy out income be reflected in this quarter?
LGND supply agreement with Amgen for Captisol: - for use in bispecific antibody: this is a rapidly growing segment across biotech - AMGN completed clinical validation on Captisol solubilized bi-Ab. - this development will significantly increase market for Captisol.
Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330 :: Ligand Pharmaceuticals, Inc. (LGND)
Hey Douche Bank, bro me, not this time you frauds.
Sean Williams gave a nice plug to LGND the other day::
"Ligand Pharmaceuticals Shares of Ligand Pharmaceuticals (NASDAQ:LGND), a biotech royalty company, have been on fire over the trailing five-year period, rising 573%. The best part is that I don't believe it's anywhere near done.
The beauty of Ligand is its business model. Rather than spending hundreds of millions or billions of dollars annually on the drug development process, Ligand licenses out its proprietary technology for a royalty on net product sales that typically ranges between 4% and 4.5%. Its best-known technology is Captisol, which helps with solubility and stability. Because Ligand focuses on licensing out its technology, it has minimal overhead expenses. In fact, the company's 2020 outlook calls for corporate gross margins in the mid-90% range!
What makes Ligand even more exciting is its "shots-on-goal" approach, as the company refers to it. Ligand has more than 90 partners spanning more than 155 compounds in various stages of the development process. Each of these therapies represents an opportunity for Ligand to "score." This means that even with a few therapies failing to succeed in clinical studies, Ligand still has plenty of opportunities for success. By comparison, it had just nine drugs being developed with its technology back in 2008 and one approved product. Today, there are 15 approved products using its technology.
Considering the foundation Ligand's management team has laid, it's not hard to imagine the company's sales exploding higher from the $109 million in reported in 2016 to the consensus of $272 million by 2020. Profit per share is also expected to top $6 per share by the turn of the decade. This hot biotech royalty stock is one you should consider gobbling up this July."
Second Phase 3 Study Shows KYPROLIS® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 7.9 Months Longer Than Patients ...
Promacta (eltrombopag) trial data reported: robust efficacy and safety in persistent and newly diagnosed immunothrombocytopenia patients:
Int J Hematol. 2017 Jun 30. doi: 10.1007/s12185-017-2275-4. [Epub ahead of print] Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
González-López TJ1, Fernández-Fuertes F2, Hernández-Rivas JA3, Sánchez-González B4, Martínez-Robles V5, Alvarez-Román MT6, Pérez-Rus G7, Pascual C7, Bernat S8, Arrieta-Cerdán E9, Aguilar C10, Bárez A11, Peñarrubia MJ12, Olivera P13, Fernández-Rodríguez A14, de Cabo E15, García-Frade LJ16, González-Porras JR17. Author information Abstract Eltrombopag is safe and effective in primary chronic ITP. However, lack of clinical trials avoids a clear demonstration of its utility in newly diagnosed and persistent ITP. Our aim here is to report Spanish results for this type of patients. We retrospectively evaluated 220 adult primary ITP patients. According to standard definition, patients were allocated to newly diagnosed (n = 30), persistent (n = 30), and chronic (n = 160) ITP. Groups were homogenous regarding most relevant parameters. 180 (90%) of 220 patients achieved a platelet response (R) with 167 (75.9%) complete responses (CR) after a 15-month follow-up. No statistical significant differences among groups but a trend towards a greater efficacy in newly diagnosed ITP were observed (93.3% of responses with 86.7% of CR). Efficacy in persistent ITP (83.3% of responses with 80.0% of CR) and chronic ITP (79.4% of responses with 73.1% of CR) was similar. 70 patients (31.8%) experienced adverse events. 15 of them were grade 3-4. Most common adverse effects were headache and hepatobiliary laboratory abnormalities (HBLAs). One persistent ITP had a venous thrombosis and one chronic ITP had grade II myelofibrosis. We consider Eltrombopag use for the early stage ITP as effective and safe as it is in chronic ITP.
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice
Eltrombopag is safe and effective in primary chronic ITP. However, lack of clinical trials avoids a clear demonstration of its utility in newly diagnosed and persistent ITP. Our aim here is to report
I have owned this for a while, and since the DB downgrade it's been a struggle, even good news sends it down a buck fifty. I only have 316 shares at 8.00. I've owned it since they bought PCOP. I sometimes think, all those partnered programs, but nothing much good seems to happen exect Promacta. and Kryopolis. We'll see, I'm on the fence, today is not good.
Posted on the SPPI board: "A new Evomela phase 2 trial, sponsored by Medical College of Wisconsin, NCT03159702, was started in July. Official Title: Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation. To remind you, current indication for Evomela is autologous stem cell transplantation in multiple myeloma. Haploidentical stem cell transplantation is allogeneic transplantation. As a treatment, it is used for many blood cancers. "The advantage of having a haploidentical transplant is that it increases the chance of finding a donor as almost everyone has at least one haploidentical relative. Relatives can usually be asked to donate stem cells much more quickly than unrelated volunteer donors, particularly when the volunteer donors live in other countries, thereby allowing transplants to be done in a more timely way."
Viking announced today they have completed enrollment in their phase 2 trial of 5211. Previous guidance stated topline results should be available in about 14 weeks. That is some time around October 18.
After long wait, New Haven's Melinta heads to market
New Haven-based Melinta Therapeutics is headed to market with its first drug, following a key approval this week from the U.S. Food and Drug Administration.
Captisol use? My research suggests that the amount of Captisol used for a given agent is ~5x the mass of the API. Anyone know differently? I am always interested as new CE products get approval to try to estimate the impact on material sales. To me, the fact that Baxdela carries a 2.5% royalty suggests that there may be a substantial Captisol component. The patient population that is addressable with Baxdela is far larger than myleoma or thrombocytopenia.
Does anyone have an idea what type of information Ligand would ask the SEC to allow them to not report until a specific time?
AMGN will present PIII data from Kyprolis+Dex trial at upcoming EHA conference: